Moomoo AI 已提取核心信息
On March 7, 2024, 180 Life Sciences Corp. announced significant changes to its Board of Directors. Sir Marc Feldmann, Ph.D., resigned from his position on the Board, effective immediately. His resignation was not due to any disagreements with the company's operations or practices. Concurrently, the company appointed Omar Jimenez and Ryan L. Smith as new independent directors, effective the same date. Both appointees will serve as Class II directors until the 2024 Annual Meeting of Stockholders. The Board also adjusted its size to five members. Jimenez, with extensive financial and compliance experience, will serve as the audit committee financial expert and chair the Audit Committee. Smith, with a background in business and public company fundraising, will chair the Compensation Committee and Nominating...Show More
On March 7, 2024, 180 Life Sciences Corp. announced significant changes to its Board of Directors. Sir Marc Feldmann, Ph.D., resigned from his position on the Board, effective immediately. His resignation was not due to any disagreements with the company's operations or practices. Concurrently, the company appointed Omar Jimenez and Ryan L. Smith as new independent directors, effective the same date. Both appointees will serve as Class II directors until the 2024 Annual Meeting of Stockholders. The Board also adjusted its size to five members. Jimenez, with extensive financial and compliance experience, will serve as the audit committee financial expert and chair the Audit Committee. Smith, with a background in business and public company fundraising, will chair the Compensation Committee and Nominating and Corporate Governance Committee. The company plans to enter into standard Indemnification Agreements with the new directors, similar to those with other directors, to cover certain legal expenses. These board changes have resulted in a majority of independent members on the Board and all three committees being fully independent, aligning with Nasdaq rules.
2024 年 3 月 7 日，180 生命科学公司宣布了其董事会的重大变动。马克·费尔德曼爵士博士辞去董事会职务，立即生效。他辞职不是因为与公司的运营或做法有任何分歧。同时，公司任命奥马尔·希门尼斯和瑞安·史密斯为新的独立董事，自同日起生效。在2024年年度股东大会之前，两位被任命者都将担任二类董事。董事会还将其规模调整为五名成员。希门尼斯拥有丰富的财务和合规经验，将担任审计委员会财务专家和审计委员会主席。史密斯具有商业和上市公司筹款背景，将担任薪酬委员会和提名与公司治理委员会主席。该公司计划与新董事签订标准赔偿协议，类似于与其他董事签订的补偿协议，以支付某些法律费用。这些董事会变动使董事会中的大多数独立成员和所有三个委员会完全独立，符合纳斯达克的规则。
2024 年 3 月 7 日，180 生命科学公司宣布了其董事会的重大变动。马克·费尔德曼爵士博士辞去董事会职务，立即生效。他辞职不是因为与公司的运营或做法有任何分歧。同时，公司任命奥马尔·希门尼斯和瑞安·史密斯为新的独立董事，自同日起生效。在2024年年度股东大会之前，两位被任命者都将担任二类董事。董事会还将其规模调整为五名成员。希门尼斯拥有丰富的财务和合规经验，将担任审计委员会财务专家和审计委员会主席。史密斯具有商业和上市公司筹款背景，将担任薪酬委员会和提名与公司治理委员会主席。该公司计划与新董事签订标准赔偿协议，类似于与其他董事签订的补偿协议，以支付某些法律费用。这些董事会变动使董事会中的大多数独立成员和所有三个委员会完全独立，符合纳斯达克的规则。
有用
没用